NCT00001036View on ClinicalTrials.gov

The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

DRUG

Thymalfasin

DRUG

Interleukin-2, Polyethylene Glycolated

DRUG

Zidovudine

Trial Locations (1)

943055107

Stanford Univ Med Ctr, Stanford

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH